Cargando…
Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America
The majority of patients with SLE in the USA have been prescribed hydroxychloroquine (HCQ). Given more recent guidelines, the availability of only one strength (200 mg tablets) may limit the flexibility and ability to accurately dose patients with lupus. The Lupus Foundation of America undertook a s...
Autores principales: | Wallace, Daniel J, Tse, Karin, Hanrahan, Leslie, Davies, Rupert, Petri, Michelle A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519405/ https://www.ncbi.nlm.nih.gov/pubmed/31168400 http://dx.doi.org/10.1136/lupus-2019-000317 |
Ejemplares similares
-
Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity
por: Askanase, Anca D., et al.
Publicado: (2019) -
Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021) -
Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey
por: Birt, Julie A., et al.
Publicado: (2021) -
Hydroxychloroquine in SLE: old drug, new perspectives
por: Dörner, Thomas
Publicado: (2010) -
SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)